Aravive (NASDAQ:ARAV) posted its quarterly earnings results on Thursday. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.50) by ($0.04), Fidelity Earnings reports.
Aravive stock traded up $0.01 during trading hours on Friday, hitting $6.53. 5,300 shares of the stock were exchanged, compared to its average volume of 23,717. The company has a debt-to-equity ratio of 0.17, a quick ratio of 11.28 and a current ratio of 11.28. The stock has a market capitalization of $75.95 million, a P/E ratio of -0.61 and a beta of 2.17. Aravive has a 12 month low of $3.07 and a 12 month high of $9.72. The business’s 50-day moving average is $7.03 and its two-hundred day moving average is $6.27.
In other Aravive news, CEO Jay Shepard sold 4,004 shares of the company’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $6.82, for a total transaction of $27,307.28. 39.80% of the stock is currently owned by corporate insiders.
Aravive, Inc, a clinical stage biotechnology company, focuses on developing therapies for solid tumors and hematologic malignancies. Its lead candidate is AVB-S6-500, a soluble Fc-fusion protein, which is in Phase 1b/2 clinical trials for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, acute myeloid leukemia, triple negative breast cancer, and pancreatic cancer.
Recommended Story: What is Cost of Debt?
Receive News & Ratings for Aravive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aravive and related companies with MarketBeat.com's FREE daily email newsletter.